Health6 hours ago
Gilead’s Trodelvy Fails Key Trial for First-Line Breast Cancer Treatment
Gilead Sciences announced on March 15, 2024, that its Phase 3 clinical trial for the antibody-drug conjugate Trodelvy did not meet its primary endpoint. The trial...
